Orexo AB - ADR - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ORXOY Over the counter 2834 https://orexo.se/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orexo AB - ADR

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US - Apr 17th, 2024 6:20 am
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled - Apr 2nd, 2024 11:24 am
Orexo publishes the Annual and Sustainability Report for 2023 - Mar 28th, 2024 7:14 am
Correction: Notice of Annual General Meeting of Orexo - Mar 22nd, 2024 8:42 am
Notice of Annual General Meeting of Orexo - Mar 15th, 2024 9:23 am
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds - Mar 13th, 2024 8:34 pm
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds - Mar 8th, 2024 7:27 am
Orexo strengthens its sustainability work by establishing a social financing framework - Mar 8th, 2024 7:24 am
Orexo and Sobi agree to advance feasibility study with AmorphOX - Feb 12th, 2024 7:13 am
Orexo Interim Report Q4 2023, incl. Full Year Report - Feb 8th, 2024 7:30 am
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC - Feb 6th, 2024 7:10 am
Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose - Nov 28th, 2023 7:31 am
Orexo Q3 2023 Interim Report - Nov 2nd, 2023 7:20 am
Orexo announces changes in the company´s Board of Directors - Oct 27th, 2023 6:42 am
Orexo´s Nomination Committee for the Annual General Meeting 2024 - Oct 26th, 2023 3:12 pm
Report from Orexo´s extraordinary general meeting - Oct 26th, 2023 2:22 pm
Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids - Oct 11th, 2023 7:04 am
Notice of Extraordinary General Meeting in Orexo AB (publ) - Oct 3rd, 2023 8:29 am
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose - Sep 18th, 2023 6:41 am
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference 2023 - Sep 5th, 2023 12:10 pm